Outsourcing

Latest News


Pharmaceutical Outsourcing Present and Future

Contract service providers must step up their game to stay competitive in increasingly complex bio/pharma market.

Pharmaceutical Outsourcing Present and Future

Navigating the Preclinical CRO Outsourcing Process

The need for preclinical testing expertise is growing as molecular complexity increases.

Navigating the Preclinical CRO Outsourcing Process

A Closer Look at Affinity Ligands

A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.

A Closer Look at Affinity Ligands

The successful auction of Quintiles raises questions for the company's new owners, Pharma Services Holdings, Inc., and the entire pharmaceutical industry with regard to strategic investments, assets to be sold, and other concerns.

Developments in 2002 such as acquisitions, excess manufacturing capacity, and less funding for biotechnology will continue to affect the industry long into the new year.

Contract Services

December's Contract Services articles include "Using Virtual Private Networks to Gain Competitive Advantage," by Mark Tuomenoska and "Outsourcing Outlook," by Jim Miller.

Contract Services

November's Contract Services articles include "Outsourcing Xbox Manufacturing," by Heather Hayes, "Outsourcing Outlook," by Jim Miller, and "Quality in Pharmacovigilance," by Brian Edwards and Jeffrey Priem.

Outsourcing Outlook

The author discusses the potential effect on CROs of pending major-pharma mergers and consolidations.

Auditing Your Contractor

When choosing a CRO, take the time to conduct an in-depth evaluation of each department, paying special attention to the quality and training of its personnel.

The author examines the concept of evaluating CRO operating performance in today's pharmaceutical industry.

The author discusses the Japanese cabinet's approval of a measure that lifts manufacturing restrictions on domestic pharmaceutical companies.

The author discusses the upcoming human research congressional debate and CROs' preparations to respond.

The author discusses recent acquisition activity in the chemistry, manufacturing, and controls (CMC) outsourcing industry.

The author discusses the current soft demand and excess capacity in the contract-manufacturing market of small molecule actives and intermediates.